SHLP-6 Research for Cancer Research
An evidence-based overview of research examining SHLP-6 in the context of cancer research. This page synthesizes findings from peer-reviewed literature.
Research Summary
In 2016, SHLP-6 increased DNA-fragmentation apoptosis in cultured human 22Rv1 prostate cancer cells and mouse NIT-1 cells. A 2010 AACR meeting abstract (DOI 10.1158/1538-7445.AM10-4537) also reported reduced growth and angiogenesis in treated 22Rv1 xenografts in SCID mice, but provided limited methods; no full animal-study report was verified in this review. Neither source establishes selective tumor killing or benefit in patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.